

# **Just – Evotec Biologics Considerations for the Design and Construction of Next Generation Biologics Manufacturing Facilities**

# Superior biologics with next generation technologies

---

Just – Evotec Biologics is providing solutions to fundamental industry challenges


---



Highest Quality



Higher Speed



Flexible Capacity




Cost Efficiency


# Just-Evotec Biologic's approach to integrated design breaks down functional silos to save time and cost

## Traditional "Silo" vs. Integrated Design approach

### Traditional "Silo" Approach




### Integrated Design Approach



# Lead antibody candidates can come from *in vivo* sources or from *in vitro* display libraries

Multiple points of entry for clients and partners

Large Full length "Humanoid"  
antibody display libraries for  
screening



**J.DISCOVERY™**




**Internal or External  
Lead Antibodies**



# Abacus is a suite of ML tools that optimize molecular design of existing lead antibodies

To improve developability and manufacturability for intensified processing

Large Full length "Humanoid"  
antibody display libraries for  
screening




J.DISCOVERY™



**Internal or External  
Lead Antibodies**

Abacus, a collection of  
*in silico* tools, is used to  
improve manufacturability  
and developability



J.MD™

ML and high throughput  
methods are used to quickly  
design highly productive  
processes




...that can be run in relatively  
small unit operations

**JP3®**

# AI generated Humanoid libraries build quality into the molecule from the point of discovery

Pre-optimized for developability and manufacturability for intensified processing

Large Full length "Humanoid"  
antibody display libraries for  
screening



**J.DISCOVERY™**

Fast from Discovery to Development-  
No need for Abacus optimization

Abacus, a collection of  
*in silico* tools, is used to  
improve manufacturability  
and developability




**J.MD™**



Internal or External  
Lead Antibodies

ML and high throughput  
methods are used to quickly  
design highly productive  
processes




...that can be run in relatively  
small unit operations

**JP3®**

# Optimized molecules designed to be therapeutics can be manufactured more efficiently and robustly

Quality begins with the molecule

Large Full length "Humanoid" antibody display libraries for screening




**J.DISCOVERY™**

Fast from Discovery to Development-  
No need for Abacus Optimization



**Internal or External  
Lead Antibodies**

Abacus, a collection of  
*in silico* tools, is used to  
improve manufacturability  
and developability




**J.MD™**

ML and high throughput  
methods are used to quickly  
design highly productive  
processes



...that can be run in relatively  
small unit operations


**JP3®**



**High Quality Molecules**




**High Quality Processes**



# Continuous processing requires intense focus on a few critical areas for success

## Focusing on the fundamentals



### Critical areas of focus


- **Aseptic Envelope** - across the entire drug substance process
- **Process Control** - maximizing productivity while delivering consistent product quality
- **Supply Chain** - rapid supply of high quality disposables and consumables at a reasonable price

### Bioburden is undetectable

| Bioburden (CFU/ 10mL) |               | Production Day |    |    |       |    |       |
|-----------------------|---------------|----------------|----|----|-------|----|-------|
| Location              | Sample Type   | 8              | 10 | 12 | 15/16 | 19 | 22/23 |
| Bioreactor            | Whole broth   | 0              |    | 0  | 0     | 0  | 0     |
| SUSV1                 | ProA Load     | 0              | 0  | 0  | 0     | 0  | 0     |
| ProA Outlet           | ProA Flowthru | 0              | 0  | 0  | 0     | 0  | 0     |
| VI Mixer              | ProA Elution  |                |    | 0  | 0     | 0  | 0     |
| SUSV2                 | Neut. VI      |                | 0  | 0  | 0     | 0  | 0     |
| SUSV3                 | AEX Load      |                | 0  | 0  | 0     | 0  | 0     |
| SUSV4                 | AEX Flowthru  |                | 0  | 0  | 0     | 0  | 0     |
| Final Pool            | ILDF Ret      |                |    | 0  | 0     | 0  | 0     |

# Clinical and commercial processes operate at the same scale to facilitate seamless transfer


J.POD® facility design reduces scale-up risk



Production from a few kilograms to metric tons in the same facility


# J.POD<sup>®</sup> manufacturing has shifted complexity and cost from the facility to the process

No central CIP and SIP systems with associated piping are required



# Processing space is expensive to build and operate, but will only be a small fraction of the facility footprint

Total ISO 7 and 8 space represents <10% of the total J.POD® plant



PODs can be added, subtracted or reconfigured to adjust capacity for maximum flexibility

# Facility shell is a new warehouse, but an appropriately designed old warehouse could also be used

Minimizing the cost of the facility envelope

---





**...when completed, it will look something like this**

Focusing investment on the manufacturing core



## Conclusions

---

- The quality of manufacturing begins with the molecule
- Successful continuous processing requires intense focus on the fundamentals
  - Aseptic Envelope
  - Process Control
  - Supply Chain
- Continuous processing in well designed, relatively inexpensive manufacturing facilities can deliver flexible capacity for manufacturing the highest quality biologics at a reasonable cost

**Questions?**

---

**Your contact:**

James N. Thomas, PhD  
EVP Global Head Biotherapeutics, President US Operations

[jim.thomas@just.bio](mailto:jim.thomas@just.bio)

---